Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study

NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:

(2015) Caroline McNeil   JNCI-Journal of the National Cancer Institute

NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:

(2015) Caroline McNeil   JNCI-Journal of the National Cancer Institute

Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials

(2014) C. Chen et al.   CLINICAL CANCER RESEARCH

Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies

(2014) C. B. Meador et al.   CLINICAL CANCER RESEARCH

The dream and reality of histology agnostic cancer clinical trials

(2014) Denis Lacombe et al.   Molecular Oncology

Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials

(2013) Scott M Berry et al.   Clinical Trials

Evaluation of Early Efficacy Endpoints for Proof-of-Concept Trials

(2013) Cong Chen et al.   Journal of Biopharmaceutical Statistics

Designing Transformative Clinical Trials in the Cancer Genome Era

(2013) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Group sequential enrichment design incorporating subgroup selection

(2013) Baldur P. Magnusson et al.   STATISTICS IN MEDICINE

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Integrating predictive biomarkers and classifiers into oncology clinical development programmes

(2011) Robert A. Beckman et al.   NATURE REVIEWS DRUG DISCOVERY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

(2009) AD Barker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Selection and bias-Two hostile brothers

(2009) Peter Bauer et al.   STATISTICS IN MEDICINE

Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug Development

(2009) Cong Chen et al.   Statistics in Biopharmaceutical Research

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

(2008) M. C. Heinrich et al.   CLINICAL CANCER RESEARCH

Accounting for patient heterogeneity in phase II clinical trials

(2007) J. Kyle Wathen et al.   STATISTICS IN MEDICINE